Table 3.

Quantification of the immune response

Treatment	Patient	Protocol	MSΔ	SDp	MSΔ/SDp	Signal adsorbeda (%)	Titres
Placebo	S002	IP	0.090	0.049	1.837	–	–
	S004	IP	0.062	0.301	0.206	–	–
	S005	IP	−0.033	0.055	−0.600	–	–
	S010	IP	0.086	0.036	2.380	–	–
	S015	AP	0.113	0.086	1.318	–	–
	S017	AP	0.055	0.065	0.841	–	–
	S020	AP	−0.076	0.118	−0.644	–	–
	S028	AP	0.872	0.065	13.421	12.72b	–
ABvac40	S001	IP	0.249	0.071	3.507	83.00	30
	S003	IP	0.315	0.064	4.927	96.72	10
	S008	IP	0.129	0.397	0.326	–	–
	S011	IP	1.852	0.066	28.061	90.95	810
	S012	AP	0.190	0.099	1.919	–	–
	S013	AP	3.635	0.097	37.474	95.54c	65,610
	S014	AP	3.093	0.104	29.737	95.52	7290
	S016	AP	2.156	0.099	21.778	95.22	270
	S018	AP	0.626	0.037	16.298	105.22	90
	S019	AP	3.526	0.099	35.616	99.63c	21,870
	S021	AP	2.265	0.156	14.519	87.90	270
	S022	AP	2.419	0.127	19.047	63.92	810
	S023	AP	3.461	0.029	119.345	99.25c	65,610
	S024	AP	1.011	0.103	9.816	72.40	90
	S025	AP	2.852	0.112	25.464	93.71	810
	S026	AP	3.230	0.104	31.058	96.81c	21,870

Abbreviations: MSΔ Maximal signal increment (in optical density), SDp Average SD from all visits of each patient, IP Initial protocol, AP Amended protocol, Aβ Amyloid-β

Non-responder patients are shown in bold

^aPre-adsorbed with 10⁻⁴ M Aβ_33–40

^bThe low percentage of adsorption of this sample suggests non-specific signal

^cPre-adsorbed with 10⁻³ M Aβ_33–40